AUPH Aurinia Pharmaceuticals Inc

$AUPH The guy who knows the most about Auph own 13 million shares. Let that sink in. Also, I’m tired of owning this stock for all these years and want to finally cash in what this thing is worth.

$AUPH Relax. Recent drops on thin volume are a classic institutional "Short-to-Accumulate" trap. Here is what's happening: 1️⃣ The Trap: Big funds can’t buy millions of shares without spiking the price. Instead, they short a small block to break support, triggering retail stop-losses. Once panic hits, their hidden buy orders absorb your cheap shares—covering shorts and accumulating long positions simultaneously. 2️⃣ Tang's Backstop: CEO Kevin Tang sold 10,000 puts at the $15 strike, creating a structural floor. If shorts try to force a cascade below $15, Tang legally steps in to swallow 1 million shares. He checkmated them. 3️⃣ Solid Ground: Q3 revenue is up 14% YoY, cash sits at $486.9M, and the Teva settlement & soon others secure a 10-year monopoly until 2036. BlackRock and Goldman are holding tight. They want you to look at the daily chart and panic. Stay strong. Know what you own. 💎🙌 Don’t be like this folks trying to get on the train…just be on it…sipping champagne!!! 🎯 $45

$AUPH The whole crux of our AUR200 application (If you read our European response) is that we use mutated domains of the BCMA to bind with extreme affinity to APRIL and BAFF that none of the prior art shows. That is enough for patentability, as we show efficacy in the pico molar range. None of this is obvious, whic htherefore makes an inventive step as per European Patent Law. That inventive step is the equivalent of showing unexpected results here in the US to obviate a 103 obviousness rejection. Again, they will be able to do so rather easily with no hiccups.

$AUPH Just to follow up, the EPO response actually mentions HSPG binding beyond just higher affinity, and there are likely other differentiators, I think people were scratching heads why it took so long before IND was filed but I think they had some homework to do with this molecule. I'm now pretty confident about this.

$AUPH From our European arguments. Again, our IP for AUR200 will be allowed pretty effortlessly is my prediction probably first in Europe potentially in a few month(s) is my guess.

$AUPH People who are actively trading this expecting this to go down a lot today but I beg to differ watch and see how it continues it is breaking out 101 in stock breakouts. Also volume was not bad yesterday they are gonna hit those 20,00$ calls by January OPEX. Dangerous times to be trading it just saying. They could literally drop universal litigation settlements and they owe us the news from the organ transplant rejection blocking covid patent news. Aurinia will do well under these macroeconomics still way undervalued.

$AUPH so what do we say folks? We going to see some action this coming week? Am I going to be able to move to Costa Rica for good? I'm going to be there for the whole month of November , so hopefully I can just buy a place while I'm down there if all goes well here.

$AUPH ****Call update Tang let us know he is on the call from the Ft Lauderdate Int’l Boat show where he is shopping for new 250’ ultra exclusive yacht. He keeps say “how you think I gonna get big $400 million boat? Not from giving AUPHy away cheap! No no…Big dolla gonna make ya holla!!! “ He is really quite the animated guy he is! Gotta go… he’s talking now about some patient stuff and 100% cure rate on 1st readout … be back! (That is PG getting thrown overboard 👀)

$AUPH Depends on what follows but there are two options: either means an escalation towards Markman or there are parallel tracks where most generics are closer to settlement than Galenicum which was the only one to react to Aurinia's filing of the discovery dispute (regarding depositions mentioned in Doc 102). It's guessing but second option is IMO more likely. AI: Aurinia is using the discovery dispute (Doc 107) to force Galenicum to produce specific documents or testimony (likely via a Rule 30(b)(6) deposition) that Aurinia believes will prove infringement or invalidate a defense. Galenicum is resisting this by requesting an extension (Doc 108), effectively arguing: "We cannot proceed with legal briefs while you are trying to force us to hand over sensitive information we believe is irrelevant or privileged." Aurinia wants the evidence; Galenicum is stalling to protect it.

$AUPH Headed to beach for mental health day. Its hard to pass up 86 degrees and sunny. Got me a 12 pack and new jigs to try out.

$AUPH is ranked #5 in healthcare quality with a score of 90. I posted these rankings yesterday, but I think they're worth sharing again. I bought yesterday because money is made when the markets are down. I used Stock Meadow's scoring model to find what I'm buying.

$AUPH Days to October 23rd, deadline for infringing parties to file claim construction briefs! 😁

$AUPH You are valuing AUPH too narrowly by focusing primarily on current LUPKYNIS sales and overlooking the additional value embedded in the business. Beyond the favorable patent outcome protecting LUPKYNIS from Teva generic competition until December 2036, Aurinia has a growing, profitable commercial franchise, international licensing and royalty income, the PRESERVE Phase 4 combination study, and substantial pipeline optionality from aritinercept, formerly AUR200, across multiple autoimmune indications. Aurinia also holds IP covering the potential use of voclosporin to treat or prevent coronavirus infections, providing additional, currently unmonetized optionality. With approximately $487M in cash and investments, positive operating cash flow and ongoing share repurchases, there is considerable value beyond LUPKYNIS sales and the patent victory alone. This will be much higher than your estimates.

$AUPH good report, huge cash pile, paid $3.7M to Kezar for Net Cash Excess CVR, no buybacks past 3 months (understandable), based on previous years total rev. for 2026 will be around $332M, below are increases in net product sales by year and cummulative sales if this +$50M trend continues to give an idea about the value of VOC in combination with very high gross margin, it's an ideal bolt-on: "For the three and nine months ended September 30, 2026, gross margin was 90% and 91%, respectively, compared to 89% and 88%, respectively, for the same periods in 2025." 21/22 +$58M 22/23 +$55M 23/24 +$58M 24/25 +$54M 25/26 +$50M (est.) 2026 $330M $330M 2027 $380M $710M ... 2036 $830M $6380M 2037 $880M $7260M ... 2041 $1080M $11280M 2042 $1130M $12410M

$AUPH I know this is AUPH but will be shocked if she doesn't close green and closer to 18.... Any bear case is WEAK!

$AUPH After 5years of holding, Sold all of my shares. Wish you guys good luck but sometimes it’s time to move on.

$AUPH Not the same thing. Friday was a patent infringement deadline for filings. News is coming. 😁

$AUPH Wonder if Tang is telling his buddies "I wouldn't want to be short over the weekend"?

$AUPH I feel like we are going to be getting a PR here sometime VERY soon... LONG overdue..

$AUPH I was interrupted from the call from the ST message ? Some folks have no sense of humor? 🤷🏻😇